Publications
2 shownEfficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
ClinicalTrials.gov Identifier: NCT02494583.
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 2,430
- Institution
- Merck & Co., Inc., Rahway, NJ, USA (United States)
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.